Navigation Links
PURE Bioscience to Present at Biocom Investors Conference

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- PURE Bioscience (OTC Bulletin Board: PURE), creators of patented silver dihydrogen citrate (SDC), the active ingredient in a revolutionary new hard surface disinfectant which kills Staph/MRSA as well as other human pathogens, announced that the Company will present at the Biocom Investor Conference on Thursday, November 1, 2007 at the San Diego Marriott Del Mar. Michael L. Krall, CEO, will discuss the Company's patented platform technology, product applications and recent company developments.


SDC is an electrolytically generated source of stabilized ionic silver. A patented new molecular entity, SDC is distinguished from competitors because of its superior efficacy and reduced toxicity. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third party products, including householder and personal care products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products.

Revolutionary Disinfecting Agent

As previously reported, PURE's EPA registered antimicrobial has eliminated Staph/MRSA infections in the Tulsa County Jail since that facility began using the hard surface disinfectant in August 2006. The jail, with 1,700 cells and more than 1,500 inmates, had historically faced challenges with Staph. Prior to its use of the SDC disinfectant, the facility experienced, on average, 12 cases of Staph infection every month. The first new disinfectant active to be registered by the EPA in more than 30 years, SDC-based products are antiviral, antifungal and antibacterial, including 24-hour residual protection against standard indicator bacteria and a 2-minute kill claim on MRSA (Methicillin- resistant Staphylococcus aureus) and VRE (Vancomycin resistant Enterococcus faecium). Moreover, SDC-based disinfectants pose little if any health hazards because they are odorless, colorless, non-corrosive, non-flammable and are compatible with other disinfecting cleaning chemicals. SDC-based disinfectant carries EPA Category IV lowest-toxicity rating.

Tremendous Pharmaceutical Potential

Last month, PURE announced the Current Good Manufacturing Practice (cGMP) certification of PURE's manufacturing facility and process for the production of its pharmaceutical-grade silver dihydrogen citrate (SDC) concentrate as an Active Pharmaceutical Ingredient (API). In addition, PURE has completed the Registration of Drug Establishment with the US Food and Drug Administration (FDA).

Clinical studies are underway related to an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by San Diego- based Therapeutics, Inc. for a hand sanitizer based upon PURE's SDC antimicrobial. PURE also granted Therapeutics, Inc. a license to develop four additional SDC-based products for the treatment and prevention of dermatological and women's health related bacterial, viral and fungal mediated diseases and conditions. Therapeutics has assumed responsibility for funding and directing the testing and regulatory processes for these selected potential FDA-regulated SDC-based products and anticipates filing four additional product INDs. Additional pharmaceutical partnership development is underway or being sought for wound and burn care products, medical devices, systemic antibiotics/antivirals and dental and veterinary applications.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Investor Contact:

Terri MacInnis, Bibicoff & Associates, Inc.


Media Contact:

Karen Sparks, Mentus


SOURCE PURE Bioscience
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):